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The homeodomain factor Pdx-1 regulates an array of
genes in the developing and mature pancreas, but
whether regulation of each specific gene occurs by a
direct mechanism (binding to promoter elements and
activating basal transcriptional machinery) or an indi-
rect mechanism (via regulation of other genes) is un-
known. To determine the mechanism underlying regu-
lation of the insulin gene by Pdx-1, we performed a
kinetic analysis of insulin transcription following ade-
novirus-mediated delivery of a small interfering RNA
specific for pdx-1 into insulinoma cells and pancreatic
islets to diminish endogenous Pdx-1 protein. insulin
transcription was assessed by measuring both a long
half-life insulin mRNA (mature mRNA) and a short half-
life insulin pre-mRNA species by real-time reverse tran-
scriptase-PCR. Following progressive knock-down of
Pdx-1 levels, we observed coordinate decreases in
pre-mRNA levels (to about 40% of normal levels at 72 h). In
contrast, mature mRNA levels showed strikingly smaller
and delayed declines, suggesting that the longer half-life
of this species underestimates the contribution of Pdx-1
to insulin transcription. Chromatin immunoprecipitation
assays revealed that the decrease in insulin transcription
was associated with decreases in the occupancies of Pdx-1
and p300 at the proximal insulin promoter. Although
there was no corresponding change in the recruitment of
RNA polymerase II to the proximal promoter, its recruit-
ment to the insulin coding region was significantly re-
duced. Our results suggest that Pdx-1 directly regulates
insulin transcription through formation of a complex
with transcriptional coactivators on the proximal insulin
promoter. This complex leads to enhancement of elonga-
tion by the basal transcriptional machinery.
Insulin is produced almost exclusively by the  cells of the
pancreatic islets of Langerhans. This restriction of insulin pro-
duction derives primarily from constraints imposed at the level
of transcription of the gene encoding preproinsulin (the insulin
gene), rather than at the level of translation of the nascent
mRNA (1, 2). Studies of the rodent insulin genes indicate that
400 base pairs (bp) of DNA 5 of the transcriptional start site
(the insulin promoter) are sufficient to confer cell type-specific
expression of insulin (3–7). Multiple discrete sequence ele-
ments within the proximal promoter region contribute to both
the specificity and magnitude of insulin expression, and these
elements are believed to serve as binding sites for several islet
transcription factors, including Pdx-1, MafA, and BETA2/Neu-
roD (see Ref. 8 for a review). In the prevailing hypothesis of
insulin transcription, the association of these transcription
factors with the promoter and their subsequent interaction
with ubiquitously expressed factors (e.g. E47 and p300) (9, 10)
leads to the recruitment of the basal transcriptional machinery
to the insulin gene. This hypothesis, however, has never been
rigorously tested for the endogenous insulin gene in islet
 cells.
The Hox-like homeodomain protein Pdx-1 is perhaps the
most extensively studied  cell transcription factor. Much of
the evidence implicating Pdx-1 in the regulation of insulin
transcription is circumstantial, and is derived from studies of
interaction of Pdx-1 with insulin promoter elements in vitro,
reporter gene expression studies in non- cell lines, and loss-
of-function studies in animals (11–17). It is unknown from
these experiments whether Pdx-1 might control insulin tran-
scription by a direct mechanism involving interaction with
upstream promoter elements or an indirect one via regulation
of other genes. In this regard, Pdx-1 is known to regulate a
complex genetic hierarchy, because its disruption in both mice
and humans results not only in the absence of insulin produc-
tion, but also in arrested development of the early pancreatic
anlage (12, 14, 18). More recent studies involving functional or
physical attenuation of Pdx-1 protein in late mouse develop-
ment or in cell lines (through targeted gene knock-out, anti-
sense, or dominant negative strategies) have suggested a po-
tentiating effect of Pdx-1 on the endogenous insulin gene (16,
19–23). On the one hand, these latter studies provide evidence
for the overall positive regulation of insulin transcription by
Pdx-1; on the other, many of these studies employed use of
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dominant negative proteins (which may have squelching effects
on gene expression) and/or involved long-term functional
knock-down of Pdx-1 (days to weeks), where its impact on a
wide range of islet genes (glut2, glucokinase, pdx-1, nkx6.1,
glucagon, and others) may have indirectly influenced insulin
expression. Few of these studies have quantitatively examined
the effect of physical knock-down of endogenous Pdx-1 in the
short term (2–4 days); those that have reveal widely conflicting
results on insulin transcription, from virtually no effect (24) to
near-complete ablation (23).
To address definitively the role of Pdx-1 in the regulation of
insulin transcription, we delivered small interfering RNA
(siRNA)1 into mouse  cell lines and islets to diminish endog-
enous Pdx-1 protein; we subsequently measured transcription
by reverse transcriptase (RT)-PCR and quantitated transcrip-
tion factor occupancy at the insulin promoter by chromatin
immunoprecipitation (ChIP). To assess precisely the transcrip-
tion of the insulin gene by RT-PCR, we employed a unique
strategy whereby we measured total mouse insulin I and II
mRNA (which reflects primarily fully processed or mature
mRNA) and a mouse insulin II pre-mRNA species containing
intron 2 by quantitative real-time RT-PCR. We demonstrate
here that intron 2-containing transcripts possess short half-
lives (9–30 min) in both mouse  cell lines and islets, whereas
mature mRNA transcript displays substantially extended half-
life (perhaps in excess of 24 h). We show that Pdx-1 knock-down
in  cell lines and islets results in a coordinate decline in
insulin transcription as measured by insulin pre-mRNA, but
not as measured by mature mRNA. This decline in insulin
transcription is accompanied by a fall in the association of
Pdx-1 and its interacting coactivator p300 with the insulin
gene, and a fall in the occupancy of RNA polymerase II (Pol II)
at the insulin coding region. Our results suggest a model
whereby Pdx-1 directly regulates insulin transcription through
formation of a complex with transcriptional coactivators on the
proximal insulin promoter. This complex appears to lead to
enhancement of transcriptional elongation by components of
the basal transcriptional machinery.
EXPERIMENTAL PROCEDURES
Antibodies—Rabbit polyclonal antiserum against p300 (N-15), RNA
polymerase II (N-20), and actin were from Santa Cruz Biotechnology.
Rabbit polyclonal antiserum against acetylated histone H3 and acety-
lated histone H4 were from Upstate Biotechnology. Rabbit polyclonal
antiserum against Pdx-1 was a gift from Dr. M. German (University of
California, San Francisco).
Cell Culture—The mouse insulinoma cell lines TC3 (25) and MIN6
(26) were maintained in Dulbecco’s modified Eagle’s medium as previ-
ously described (26, 27) in 6-well tissue culture plates at a density of 5 
105 cells/well. Mouse pancreatic islets were provided by the University
of Virginia Diabetes Center Islet Isolation Core Facility. Islets were
picked by hand from collagenase-digested 6–8-week-old CD-1 mouse
pancreas (28) using a protocol approved by the Institutional Animal
Care and Use Committee. Islets were cultured in RPMI medium con-
taining 25 mM glucose overnight, then plated in 6-well tissue plates at
a density of 150 islets/well.
For RNA decay experiments, cells were incubated in medium con-
taining 0.1 mM glucose for 4 h, then switched to fresh medium contain-
ing either 0.1 or 25 mM glucose for 30 min and subsequently treated
with 50 g/ml of actinomycin D. At the times indicated, cells were
washed once with PBS and processed for RNA isolation using the
RNeasy® kit (Qiagen) according to the manufacturer’s instructions. For
isolation of whole cell extract, cells were washed twice in PBS and
subsequently lysed directly in the plates by adding 50 l of Laemmli
buffer containing 4% SDS.
Adenoviral Vector Construction and Infection—A recombinant ade-
novirus (Ad-siPdx) containing an siRNA sequence (5-GAAAGAGGAA-
GATAAGAAA-3) corresponding to nucleotides 706–724 of pdx-1 (Gen-
BankTM accession number NM_022852) was recently prepared2 using
vector EH006 as described (29). An siRNA sequence targeting the
Photinus pyralis luciferase gene, GL2 (30), was cloned into adenovirus
(Ad-siLuc) for use as controls. Resulting adenoviruses were purified
using the AdenoX® purification kit (BD Biosciences). Infectious titers of
virus, as determined by end point dilution assay in HEK293 cells, were
on the order of 1010–1011 pfu/ml.
For adenoviral transduction of insulinoma cell lines, TC3 and MIN6
cells were cultured overnight at a density of 5  105 cells/well in 6-well
tissue culture plates as described above, followed by addition of recom-
binant adenoviruses at a multiplicity of infection of 2500 pfu/cell.
After 5 h, virus-containing medium was removed and cells were washed
once with PBS and cultured in fresh medium. At the times indicated,
cells were processed for isolation of total RNA or whole cell extracts, as
described above. Islets were transduced with adenoviruses as described
previously (29). Briefly, islets were maintained in 6-well plates at a
density of 150 islets/well; adenoviruses were added at a multiplicity of
infection of 1.3  106 pfu/islet in a total of 0.8 ml of serum-free medium.
After 24 h, 2 ml of fresh medium containing serum was added and the
islets were incubated for an additional 48 h, after which they were
processed for total RNA isolation and whole cell extracts.
Real-time RT-PCR—Five micrograms of total RNA from  cell lines
and islets were reverse transcribed at 37 °C for 1 h using 15 g of
random hexamers, 0.5 mM dNTPs, 5 first strand buffer, 0.01 M di-
thiothreitol, and 200 units of Moloney murine leukemia virus reverse
transcriptase (Invitrogen) in a final reaction volume of 20 l. Real-time
RT-PCR was performed as described previously (27, 31, 32), but using
forward and reverse primers to amplify mature insulin mRNA (5-TG-
GCTTCTTCTACACACCCAAG-3 and 5-ACAATGCCACGCTTCTGC-
C-3), insulin pre-mRNA (5-GGGGAGCGTGGCTTCTTCTA-3 and 5-
GGGGACAGAATTCAGTGGCA-3), or -actin (5-AGGTCATCACTAT-
TGGCAACGA-3 and 5-CACTTCATGATGGAATTGAATGTAGTT-3).
PCR were cycled 50 times using the following conditions: 95 °C for 15 s,
64 °C for 1 min. Homogeneity of products from each reaction was
confirmed by melt curve analysis (as shown in Fig. 1C). Pdx-1 mRNA
levels in reverse-transcribed RNA were determined using the Assay on
Demand® RT-PCR kit (product number Mm00435565_m1, Applied
Biosystems) according to the manufacturer’s instructions.
Amplified products from initial PCR were subcloned into the T/A
cloning vector pCR2.1 (Invitrogen), and 3–4 clones were sequenced to
confirm the identity of the amplified product. The threshold cycle (CT)
methodology (27, 31) was used to calculate relative quantities of mRNA
products from each sample; all samples were corrected for total input
RNA by normalizing CT values to the CT value of -actin message.
These corrections were verified by quantitation of total RNA in each
sample by fluorescence using RiboGreen® dye (Molecular Probes).
Primers for mature mRNA and pre-mRNA displayed equal effi-
ciency for amplification of target DNA as determined in the following
manner: total genomic DNA from TC3 cells was used as a template
for PCR using each primer set. Because the mature mRNA primers
recognize both mouse insulin I and insulin II (total  4 copies in
genomic DNA), whereas pre-mRNA primers recognize only mouse
insulin II (total  2 copies in genomic DNA), it would be expected that
CT values would occur 1 cycle sooner for mature mRNA primers than
for pre-mRNA primers (assuming both primer sets amplified with
equal efficiency). We observed amplification of mature mRNA with a
CT of 17, and amplification of pre-mRNA with a CT of 18. This
difference of 1 cycle was reproducible across a range of dilutions of
genomic DNA.
Mathematical Modeling of RNA Decay—RNA decay curves shown in
Fig. 2 were optimized (by a modified Gauss-Newton nonlinear least
squares algorithm) (33) to an exponential decay function of the form,
y(t)  expt   c (Eq. 1)
where y(t) is the observed time series data; t is time;  is the magnitude
of exponential decay;  is the lifetime of the exponential decay process;
and c is an additive, offset constant.
Quantitative ChIP—ChIP assays, including quantitation of co-immu-
noprecipitated DNA fragments by real-time PCR, were performed as1 The abbreviations used are: siRNA, small interfering RNA; Ad-
siLuc, adenovirus encoding siRNA against luciferase mRNA; Ad-siPdx,
adenovirus encoding siRNA against pdx-1 mRNA; ChIP, chromatin
immunoprecipitation; Pol II, RNA polymerase II; RT, reverse tran-
scriptase; PBS, phosphate-buffered saline; pfu, plaque-forming unit.
2 J. Schisler, P. Jensen, D. Taylor, T. Becker, F. Knop, M. German,
G. Weir, D. Lu, R. Mirmira, and C. Newgard, submitted for publication.
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described previously (27, 31, 32) with the following modifications. TC3
cells and islets were plated in 6-well dishes at 5  105 cells/well or 150
islets/well, respectively, for infection with adenovirus (as described
above). Following incubation with adenovirus for 72 h, each well was
washed with PBS, cross-linked for 15 min in 1% formaldehyde (in PBS),
then all wells were pooled. Pooled samples were sonicated as described
(27) in 600 l of sonication buffer to yield chromatin fragments of
500–800 bp in length. Approximately 150 l of sonicated chromatin
was diluted to 1 ml in ChIP buffer (27) and subject to immunoprecipi-
tation with the antibodies indicated in Fig. 6. 15 l of sonicated sample
was saved for quantitation of input chromatin. ChIP assays were per-
formed on at least 3 independent occasions; for each ChIP assay, pro-
moter samples were quantitated in triplicate as previously described
(27, 31) using SYBR Green I-based real-time PCR. Data in Fig. 6 are
presented as percent of input DNA recovered. Forward and reverse
primer sequences, respectively, used for PCR were: proximal insulin
promoter: 5-TACCTTGCTGCCTGAGTTCTGC-3 and 5-GCATTTTC-
CACATCATTCCCC-3; insulin coding sequence: 5-TGGCTTCTTCTA-
CACACCCAAG-3 and 5-ACAATGCCACGCTTCTGCC-3.
Immunoblot Analysis—Whole cell extracts from cell lines and islets
were prepared as described above. Aliquots of 5 g of protein were
resolved by electrophoresis on a 15% SDS-polyacrylamide gel followed
by immunoblot analysis using anti-Pdx-1 or anti-actin antibodies (both
at 1:5000 dilution). Western blots were visualized using the ECL-Plus®
FIG. 1. Real-time RT-PCR amplification of insulin pre-mRNA and mature mRNA. A, schematic representation of the mouse insulin II
gene, indicating positions of PCR primers (Tf, Tr, Pf, and Pr) relative to the introns and exons of the gene. B, a 2% agarose gel showing amplification
of products from reverse-transcribed islet RNA corresponding to insulin pre-mRNA and mature mRNA. C, SYBR Green I melt curve analysis of
products following real-time PCR amplification from reverse-transcribed islet RNA. D and E, real-time PCR threshold cycles demonstrating
linearity of amplification of pre-mRNA (D) and mature mRNA (E) from serial 2-fold dilutions of islet RNA.
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system (Amersham Biosciences), and quantitated by densitometry us-
ing 1D® software (Kodak).
RESULTS
Quantitation of Mature insulin mRNA and insulin
Pre-mRNA and Determination of Their Biologic Half-lives in 
Cells—In most mammals (including the human), the gene en-
coding preproinsulin (insulin) exists as a single gene contain-
ing two introns. However, in rats and mice the gene has un-
dergone a duplication event during evolution, resulting in two
homologous non-allelic genes (insulin I and insulin II) (1, 2).
Similar to other mammals, the rodent insulin II gene contains
two introns (see Fig. 1A), whereas the insulin I gene lacks the
second intron. Prior studies have suggested very long half-lives
(up to perhaps 80 h) of many spliced and unspliced forms of
insulin mRNAs in mouse islets and  cell lines (34–38); a
notable exception, however, is the insulin II intron 2-contain-
ing transcript, which appears to have a half-life on the order of
minutes (37). Because both insulin genes appear to be coordi-
nately regulated in the  cell (39, 40), we hypothesized that
measurement of a short half-life insulin II transcript species
would more accurately reflect immediate changes (particularly
decreases) in overall transcriptional rates that might occur in
our studies of insulin gene regulation.
To measure insulin mRNA species, we designed two primer
sets (shown in Fig. 1A) for quantitative real-time RT-PCR. The
primer set Tf/Tr was designed to amplify a 130-bp sequence in
exon 2 of the mouse insulin I and II genes, and therefore
targets both spliced and unspliced mRNA (total mRNA). Be-
cause unspliced insulin mRNA represents a very small fraction
of total insulin mRNA (37), this primer set can be viewed as
FIG. 2. insulin transcript half-lives. TC3 cells, MIN6 cells, and islets in either 0.1 or 25 mM glucose were incubated with actinomycin D for
the times indicated, then total RNA from the cells was isolated, reverse-transcribed, and subject to quantitation for either mature insulin mRNA
(panel A) or insulin pre-mRNA (panel B) by real-time PCR. To correct for variations in input RNA, all data were normalized to the quantity of
-actin message (also determined by real-time PCR). The half-lives (t1⁄2) indicated in panel B were determined by fitting the data to an exponential
decay model, as detailed under “Experimental Procedures.” Experiments were performed on a minimum of three independent occasions. The curves
in panel B represent the best-fit model.
TABLE I
Real-time RT-PCR threshold cycles (CT) for mouse mature insulin mRNA and insulin II pre-mRNA in  cell lines and islets
Insulin II pre-mRNAa Mature insulin mRNAa Relative abundanceb
(pre-mRNA:mature mRNA)RT RT RT RT
TC3 cells 17.5  0.1 35 12.3  0.6 40 0.027
MIN6 cells 20.3  0.8 35 13.9  1.4 40 0.012
Islets 28.4  2.6 35 14.2  2.7 40 5.3  105
a To correct for variations in input RNA, threshold cycles were normalized to the actin mRNA threshold cycle in each sample, which was
approximately 17 for all cell types.
b Relative abundance was calculated using the following formula: 2[CT(mRNA)CT(pre-mRNA)]. As noted under “Experimental Procedures,” RT-PCR
primers for insulin mRNA and pre-mRNA were equally efficient.
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representing primarily mature (or fully spliced) mRNA. The
primer set Pf/Pr was designed to amplify an 82-bp fragment
spanning the exon 2/intron 2 boundary, thereby targeting only
a specific unspliced mRNA (pre-mRNA) of insulin II containing
intron 2. Fig. 1B shows that PCR amplification of both species
of mRNA from reverse-transcribed total islet RNA results in
homogenous products of expected molecular weight. Primers
were subsequently used for SYBR Green I-based real-time PCR
(27, 31). Fig. 1C confirms, by melt curve analysis, that homog-
enous products were obtained following 50 cycles of PCR; Fig.
1, D and E, shows that the real-time PCR quantitation of both
insulin pre-mRNA and mature mRNA was linear over the
relatively narrow range of total RNA concentrations observed
in our studies, thereby demonstrating the reproducibility and
linearity of our real-time assay in distinguishing small differ-
ences in target mRNA quantities. Similar linearity data were
obtained for the real-time amplification of -actin message, and
for all messages amplified from reverse-transcribed RNA iso-
lated from two mouse  cell-derived insulinoma cell lines, TC3
and MIN6 (data not shown).
Table I shows the real-time PCR amplification threshold
values for insulin mature mRNA and pre-mRNA in mouse
insulinoma cell lines and islets maintained in 25 mM glucose.
Interestingly, these data reveal no substantial differences in
the relative amounts of mature insulin mRNA in these cells,
but do show striking differences in pre-mRNA levels. Based on
the calculated ratio of pre-mRNA to mature mRNA, the quan-
tities of pre-mRNA are substantially lower than mature mRNA
in all cell types. (Importantly, as noted under “Experimental
Procedures,” both primer sets appeared to have identical am-
plification efficiencies based on a comparison of threshold val-
ues from genomic DNA.) However, although this ratio was
similar for the two insulinoma cell lines, by comparison it was
lower by 200–500-fold in islets. These data suggest that the cell
lines produce initial transcripts in far greater quantity than
islets, a finding consistent with their tumorigenic origin.
To determine the biologic half-lives of insulin mRNA species,
TC3 cells, MIN6 cells, and mouse islets were treated with
actinomycin D to block transcriptional elongation, and cells
were harvested at various time points for isolation and quan-
FIG. 3. siRNA-mediated knock-
down of Pdx-1 in insulinoma cell
lines. TC3 and MIN6 cells were left un-
infected or infected with adenovirus en-
coding siRNA against either luciferase
(Ad-siLuc) or pdx-1 (Ad-siPdx) at a multi-
plicity of infection of 2500 pfu/cell. Cells
were harvested at the time points indi-
cated for isolation of either total RNA or
whole cell extract. A, quantitation of
pdx-1 mRNA by real-time PCR in infected
cells. To correct for variations in input
RNA, data were normalized to the quan-
tity of -actin message (also determined
by real-time PCR). Data at each time
point represent percent of pdx-1 mRNA
relative to uninfected cells (for which lev-
els of pdx-1 mRNA did not change signif-
icantly over the time course). B, repre-
sentative immunoblot for Pdx-1 and
-actin proteins from whole cell extracts
of infected TC3 and MIN6 cells. C, phos-
phorimager quantitation of Pdx-1 protein
levels from Western blots shown in panel
B. Data represent the average of at least
three independent experiments.
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titation of mRNAs. As shown in Fig. 2, mature insulin mRNA
was observed to have an extended half-life (no discernable
decay after 60 min) in all cell types grown under high (25 mM)
or low (0.1 mM) glucose conditions. By contrast, intron 2-con-
taining pre-mRNA showed short half-lives of 9, 14, and 18 min
in TC3, MIN6, and islet cells, respectively, under high glucose
conditions (see Fig. 2B). In TC3 cells and islets, this half-life
was extended about 1.5-fold (to 13 and 32 min, respectively)
under low glucose conditions, in confirmation of prior studies
showing that glucose concentration can affect insulin mRNA
processing rates (37). The data in Fig. 2 were normalized to
levels of -actin mRNA, which showed no discernable decay
during the time course (data not shown).
siRNA-induced Knock-down of Pdx-1 Levels in  Cell Lines
Coordinately Diminishes insulin Pre-mRNA Levels—To deter-
mine the role of Pdx-1 in insulin transcription, we knocked
down endogenous Pdx-1 protein in  cell lines and subse-
quently analyzed cells for insulin transcription by real-time
RT-PCR. To knock-down Pdx-1 levels, we treated cells with an
adenovirus encoding siRNA specific for pdx-1 (Ad-siPdx). Fig.
3A shows that Ad-siPdx treatment caused a time-dependent
decrease in pdx-1 mRNA levels to a nadir of 20% of starting
concentrations in both TC3 and MIN6 cells. Conversely, un-
treated cells or cells treated with an adenovirus encoding
siRNA specific for luciferase (Ad-siLuc) showed no change in
pdx-1 mRNA levels (Fig. 3A). The fall in pdx-1 mRNA levels in
Ad-siPdx-treated cells corresponded to a decrease in Pdx-1
protein in both cell types as assessed by immunoblot analysis,
to levels 5–15% of those observed in control cells (Fig. 3, B
and C).
To assess the effect of Pdx-1 knock-down on insulin gene
transcription in TC3 and MIN6  cells, we measured both
insulin mature mRNA and pre-mRNA during a time course
following Ad-siPdx or Ad-siLuc treatment (or no treatment). As
shown in Fig. 4A, Ad-siPdx treatment resulted in no significant
decline in mature insulin mRNA levels over the first 48 h of the
experiment, and a decline of only 30% at 72 h relative to control
cells. These results are comparable with a previous report
demonstrating virtually no decline in insulin message in both
cell types following antisense RNA-induced Pdx-1 knock-down
(24). In striking contrast, however, pre-mRNA levels in both
cell types were decreased by 40% 48 h after Ad-siPdx treat-
ment, and by 60% 72 h after treatment. The decreases in
pre-mRNA levels precisely paralleled the fall in Pdx-1 protein
levels observed by immunoblot analysis (cf. Fig. 3C), highlight-
ing the rapid effect of Pdx-1 knock-down on insulin transcrip-
tion in  cell lines. Importantly, half-lives of insulin pre-mRNA
and mature mRNA appear unchanged in cells treated with
Ad-siPdx and Ad-siLuc, based on actinomycin D experiments
performed at 72 h after viral treatment (data not shown).
siRNA-induced Knock-down of Pdx-1 in Primary Mouse Is-
lets Diminishes insulin Pre-mRNA Levels—To determine the
contribution of Pdx-1 to insulin transcription in primary cells,
we treated intact mouse islets with Ad-siPdx and compared
these to Ad-siLuc-treated and untreated control islets. As
shown in Fig. 5A, treatment of islets with Ad-siPdx for 72 h
resulted in a 70% decrease in pdx-1 mRNA compared with
control islets. This reduction in pdx-1 mRNA corresponded to
70% reduction in Pdx-1 protein levels compared with control
islets (Fig. 5B). We next measured both mature insulin mRNA
and insulin pre-mRNA by real-time RT-PCR from total RNA
isolated from Ad-siPdx-treated and control islets at 72 h. As
shown in Fig. 5C, mature mRNA levels decreased by 25%
compared with controls, whereas pre-mRNA levels declined by
FIG. 4. Quantitation of mature insu-
lin mRNA and insulin pre-mRNA in
siRNA-treated  cell lines. TC3 and
MIN6 cells were left uninfected or in-
fected with adenovirus encoding siRNA
against luciferase (Ad-siLuc) or pdx-1 (Ad-
siPdx) as in Fig. 3, and total RNA was
isolated from cells at the indicated time
points. Levels of mature insulin mRNA
(A) or insulin pre-mRNA (B) were quan-
titated by real-time PCR. To correct for
variations in input RNA, data were nor-
malized to the quantity of -actin mes-
sage (also determined by real-time PCR).
Data at each time point represent percent
of mRNA or pre-mRNA relative to unin-
fected cells (for which levels of these spe-
cies did not change significantly over the
time course). Asterisk (*) signifies that the
value for Ad-siPdx-treated cells is statis-
tically different (p 	 0.05) from the corre-
sponding value for untreated or Ad-siLuc-
treated cells. Data represent the average
of at least three independent experiments.
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50%. These results are comparable with those obtained in the
 cell lines, and suggest that insulin transcription in primary
isolated islets is similarly regulated by Pdx-1. Taken together,
the results from  cell lines and islets strongly suggest that
Pdx-1 directly regulates insulin transcription and that insulin
pre-mRNA levels reflect this regulation more accurately.
Recruitment of Pdx-1, p300, and RNA Polymerase II to the
insulin Promoter—To determine the mechanism underlying
insulin gene activation by Pdx-1, we examined the association
of Pdx-1, p300, and RNA polymerase II to the insulin promoter
in untreated, Ad-siLuc-, and Ad-siPdx-treated TC3 cells and
mouse islets by the ChIP assay. We and others have previously
demonstrated by ChIP that Pdx-1 and p300 specifically occupy
the proximal insulin promoter of TC3 cells (27, 31, 41). 72 h
following Ad-siPdx treatment, we observed an 80% reduction in
Pdx-1 occupancy at the proximal promoter in TC3 cells and a
reduction of Pdx-1 occupancy to background levels in mouse
islets (Fig. 6, A and B, respectively); these effects were not
observed in Ad-siLuc-treated or untreated control islets. The
decrease in Pdx-1 at the proximal promoter in TC3 cells was
accompanied by a 40% reduction in the occupancy of p300 at
the proximal insulin promoter (Fig. 6C). Because we did not
observe any decrease in the levels of p300 in Ad-siPdx-treated
cells by immunoblot (Fig. 6C, inset), these results suggest that
the knock-down of Pdx-1 impairs the recruitment of p300 to the
proximal promoter. (Because of low signal-to-noise ratios, we
were unable to obtain meaningful data on p300 recruitment in
islets.) Although p300 has histone acetyltransferase activity
(42), we did not observe significant falls in histone H3 or H4
acetylation at the proximal insulin promoter during the time
course of these studies in TC3 cells (data not shown).
At least one of the mechanisms underlying the action of
transcription factors and coactivators is their effect on the
initiation and/or elongation of transcription by RNA polymer-
ase II (Pol II) (43). We therefore examined the effect of Pdx-1
knock-down on Pol II occupancy at the insulin promoter by
ChIP. Interestingly, at the proximal insulin promoter (where
transcriptional initiation complex formation is expected to oc-
cur), we observed no significant change in Pol II occupancy
following Ad-siPdx treatment of TC3 cells (Fig. 6D). However,
Pol II occupancy within the downstream coding region of the
insulin gene was diminished by almost 4-fold following Ad-
siPdx treatment (Fig. 6E), suggesting that loss of Pdx-1 impairs
transcriptional elongation by Pol II.
DISCUSSION
In this report, we provide evidence that the insulin gene is a
direct downstream target of the pancreatic homeodomain tran-
scription factor Pdx-1. Prior to our work, evidence supporting a
direct role of Pdx-1 on insulin transcription derived primarily
from electrophoretic mobility shift analysis in vitro and studies
of reporter gene expression in mammalian cells (11–13, 15, 16).
However, those and other studies did not examine the role of
endogenous Pdx-1 protein upon transcription of the native,
chromatin-embedded insulin gene. In this study, we employed
a unique RT-PCR strategy following siRNA delivery to study
transcription of the native insulin gene in the absence of
Pdx-1 protein.
One complication to studying the regulation of insulin tran-
scription by RT-PCR or Northern blot analysis is that such
assays are strongly influenced by the high levels and extended
half-life of the mature insulin mRNA in insulinoma cell lines
and islets. It has been estimated that the  cell contains up to
40,000 insulin transcripts, exceeding even the number of -ac-
tin transcripts (36, 37). Our results here appear to support this
observation (Table I), and indicate further that the half-life of
insulin mRNA is considerably in excess of 60 min, but in all
likelihood is closer to 30–80 h, as reported by many other
investigators (34–38). Thus, an important implication of our
studies is that if insulin transcription is studied solely by
methods that quantitate total mRNA, it will be difficult to
interpret the effect of putative transcriptional modulators
(transcription factors, glucose, cAMP, etc.), because several
days may be necessary to observe changes in the rather large
insulin mRNA content in  cells. In this context, an earlier
report (24) that showed no effect of Pdx-1 knock-down on insu-
lin transcription (as assessed by Northern blot analysis) in
MIN6 and TC1 cells is clarified. Indeed, our studies confirm
that knock-down of Pdx-1 levels by 80–90% causes only a 30%
reduction in mature insulin mRNA over 72 h, and well after
clear suppression of Pdx-1 has occurred. By themselves, these
data may raise doubt as to the immediate role of Pdx-1 in
insulin transcription.
To overcome the potential barrier imposed by the long half-
life of insulin mRNA, we examined whether a pre-mRNA spe-
cies with a shorter half-life could be used to study insulin
transcription. In this respect, formation of pre-mRNAs are
FIG. 5. siRNA-mediated knock-down of Pdx-1 in isolated
mouse islets. Approximately 150 mouse islets were untreated or
treated with adenovirus encoding siRNA against luciferase (Ad-siLuc)
or pdx-1 (Ad-Pdx) at a multiplicity of infection of 1.3  106 pfu/islet.
Islets were harvested at 72 h for isolation of total RNA or whole cell
extract. A, quantitation of pdx-1 mRNA by real-time PCR in infected
islets. To correct for variations in input RNA, data were normalized to
the quantity of -actin message (also determined by real-time PCR).
Data represent percent of pdx-1 mRNA relative to untreated cells (set
at 100%). B, immunoblot for Pdx-1 and -actin proteins from whole cell
extracts of infected islets. Data from two independent infections are
shown. C, levels of mature insulin mRNA or insulin pre-mRNA were
quantitated by real-time PCR, and normalized to the quantity of -actin
message. Data represent percent of mRNA or pre-mRNA relative to
uninfected cells (set at 100%). Asterisk (*) signifies that the values are
statistically different for the comparisons indicated (p 	 0.05). Data
represent the average of at least three independent experiments.
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more closely linked to transcription, because no intervening
processes such as splicing or cytoplasmic export necessarily
occur. Quantitation of such short half-life pre-mRNAs have
been used as a reflection of acute transcriptional regulation in
other systems such as the LH, FSH, and follistatin genes,
and can closely mimic results obtained from nuclear run-off
assays (44, 45). We demonstrate here by real-time RT-PCR that
the intron 2-containing transcripts of mouse insulin II possess
remarkably short half-lives (on the order of minutes) in both 
cell lines and islets, a finding consistent with a prior study
using the branched DNA assay methodology (37). Interest-
ingly, pre-mRNA levels (relative to mature mRNA levels) ap-
pear to be much lower in islets than insulinoma cell lines
(Table I). Although this finding suggests that insulin transcrip-
tion rates are lower in islets compared with insulinoma cells, it
should be noted that our studies examined only relative mes-
sage levels in intact islets, which additionally contain endo-
crine cell types other than  cells. In this regard, other studies
using different methodologies have found higher pre-mRNA
and mature mRNA levels in islets on a per-cell basis (37).
In contrast to the lesser and delayed decrease in mature
insulin mRNA following knock-down of Pdx-1, the decline in
intron 2-containing insulin pre-mRNA levels are observed in
close association with the fall in Pdx-1 levels. This finding has
four important implications: 1) pre-mRNA levels reflect a
downward trend in transcription much sooner (by about 24 h)
than mature mRNA levels, a finding that is explained by the
shorter half-life of the pre-mRNA species; 2) the close associa-
tion of insulin pre-mRNA and Pdx-1 levels, in conjunction with
the decrease in occupancy of Pdx-1 at the proximal insulin
promoter, points to the insulin gene as an immediate down-
stream target of Pdx-1 (as opposed to a target downstream of a
secondary or tertiary gene expression event); 3) our data sug-
gest that a striking fraction (at least 60%) of insulin transcrip-
tional activity is dependent upon Pdx-1 action, notwithstand-
ing the fact that a host of  cell-specific transcription factors
are believed to participate at the promoter (8). We believe these
findings must be considered in the context of transcription
factor cooperativity at the insulin promoter. Thus, the loss of
cooperative interactions between Pdx-1 and factors such as
BETA2/NeuroD and E47 (15) may underlie the significant fall
in transcriptional rate; and 4) our findings in the  cell lines
appear to be similar to those in primary mouse islets, suggest-
ing that the mechanism by which Pdx-1 regulates insulin tran-
scription in insulinoma cells is likely to be very similar to that
in the primary cell type.
The mechanism governing transcriptional activation by
Pdx-1 has been the subject of intense investigation over the
FIG. 6. Association of Pdx-1, p300,
and RNA polymerase II with the in-
sulin gene. TC3 cells or islets were in-
fected with adenovirus encoding siRNA
against either luciferase (Ad-siLuc) or
pdx-1 (Ad-siPdx) for 72 h, and cells were
subsequently harvested for ChIP as de-
tailed under “Experimental Procedures.”
Schematic diagrams of the insulin gene
above the panels indicates the DNA frag-
ments (and their positions in bp relative
to the transcriptional start site at 1)
that were amplified by real-time PCR fol-
lowing ChIP. A and B, recovery of the
proximal insulin promoter fragment
(300 to 462 bp) following ChIP using
antibody (Ab) against Pdx-1 and extracts
from infected TC3 cells (A) or islets (B).
C, recovery of the proximal promoter frag-
ment following ChIP using p300 Ab and
extracts from infected TC3 cells. Inset
shows an immunoblot for p300 from TC3
cells treated with no virus (lane 1) or Ad-
siPdx (lane 2). D and E, recovery of the
proximal promoter fragment (D) or a dis-
tal fragment from the insulin coding re-
gion (E) following ChIP using RNA po-
lymerase II (Pol II) Ab and extracts from
infected TC3 cells. All data represent
recovery, in percent, of each DNA frag-
ment relative to total input DNA. Asterisk
(*) signifies that the value for Ad-siPdx-
treated cells is statistically different from
the corresponding value for Ad-siLuc-
treated cells (p 	 0.05). Data represent
the average of at least three independent
experiments.
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years. Pdx-1 is known to have a uniquely functioning transac-
tivation domain in its amino terminus (46), and to interact with
a host of other transcription factors and cofactors (9, 15, 47, 48).
Importantly, the net effect of Pdx-1 action at any putative
target promoter (degree of transcriptional activation or even
repression) likely depends upon the overall balance of these
interactions. The coactivator p300 interacts with Pdx-1 and is
thought to enhance insulin transcriptional activity through
multiple mechanisms, including the recruitment and activa-
tion of components of the basal transcriptional machinery and
histone/protein acetylation (9, 31, 49–51). Our studies show
that the association of p300 with the insulin promoter is di-
minished upon knock-down of Pdx-1, consistent with the notion
that its interaction with Pdx-1 may be important in its recruit-
ment to the promoter. Although this decrease in p300 occu-
pancy was not associated with significant changes in histone
acetylation at the insulin gene, we cannot rule out the possi-
bility that acetylation of other proteins (e.g. basal transcrip-
tional components) by p300 is crucial for insulin transcription.
Importantly, the association of p300 with the insulin promoter
is only partially eliminated following Pdx-1 knock-down,
thereby emphasizing the role of other transcription factors at
the promoter that are likely to recruit p300, including BETA2/
NeuroD and E47 (10).
Pol II is a crucial component of the basal transcriptional
machinery in mammalian cells and is believed to be physically
or functionally “bridged” to sequence-specific transcription fac-
tors by cofactors such as p300 (43). Despite the decreases in
p300 recruitment and insulin transcription following Pdx-1
knock-down, we did not observe significant changes in the
occupancy of Pol II to the proximal insulin promoter; however,
the occupancy of Pol II in the downstream coding region was
reduced significantly by almost 4-fold. Because it is known that
sequence-specific transcription factors can differentially affect
either initiation or elongation by Pol II in other systems (52–
54), our results suggest a model (see Fig. 7) whereby Pdx-1
directly interacts with sequence elements of the insulin pro-
moter and (perhaps in conjunction with its interacting proteins
p300, BETA2/NeuroD, and E47) may ultimately be crucial to
promoting transcriptional elongation at the insulin gene, at
least in insulinoma cells.
Taken together, our studies validate the hypothesis that islet
transcription factors interact with upstream regulatory se-
quences in the insulin promoter, form complexes with ubiqui-
tously expressed factors, and subsequently activate compo-
nents of the basal transcriptional machinery (Fig. 7). In the
context of disease, our data point to deficiency at the transcrip-
tional level as one factor underlying the insulin secretory defect
observed in conditions of functional Pdx-1 deficiency, such as
human maturity onset diabetes of the young type 4 syndrome
(MODY4) (55). Central to our studies is the measurement of a
less abundant insulin II pre-mRNA species, in addition to
mature mRNA, as a means of assessing changes to insulin
transcriptional rates. We anticipate that measurement of this
pre-mRNA species will likely clarify findings in future studies
examining transcriptional regulation of the endogenous
insulin gene.
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